Rubius Therapeutics is developing Red-Cell Therapeutics™ (RCTs™) as a new class of medicines to address a wide array of indications, with leading applications in cancer, rare and autoimmune disease, as well as additional potential in hemophilia, infectious and metabolic diseases.
Type | Public | |
Founded | 2013 | |
HQ | Cambridge, MA, US | Map |
Website | rubiustx.com |
USD | |
---|---|
Net income (Q2, 2020) | (37.9m) |
EBIT (Q2, 2020) | (37.7m) |
Market capitalization (21-Jan-2021) | 747.7m |
Closing stock price (21-Jan-2021) | 9.2 |
Cash (30-Jun-2020) | 129.2m |
EV | 737.5m |
USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|
General and administrative expense | 1.1m | 5.8m | 16.3m | 13.2m | 13.5m | 13.8m | 15.0m | 12.7m | 11.6m |
R&D expense | 3.7m | 9.7m | 12.0m | 14.4m | 20.9m | 27.5m | 33.5m | 36.2m | 26.1m |
Operating expense total | 4.8m | 15.4m | 28.2m | 27.6m | 34.4m | 41.3m | 48.5m | 48.9m | 37.7m |
EBIT | (4.8m) | (15.4m) | (28.2m) | (27.6m) | (34.4m) | (41.3m) | (48.5m) | (48.8m) | (37.7m) |
USD | Q1, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 |
---|---|---|---|---|---|---|---|---|---|
Net Income | (4.9m) | (15.3m) | (44.4m) | (62.0m) | (32.6m) | (72.0m) | (119.0m) | ||
Depreciation and Amortization | 48.0k | 227.0k | 502.0k | 879.0k | 661.0k | 1.4m | 2.3m | 1.8m | 3.6m |
Accounts Payable | 937.0k | 452.0k | 3.0m | 2.4m | (966.0k) | (4.7m) | 3.2m | 905.0k | 3.1m |
Cash From Operating Activities | (3.1m) | (10.9m) | (20.8m) | (38.6m) | (22.9m) | (52.7m) | (81.5m) | (40.0m) | (68.6m) |
USD | FY, 2016 |
---|---|
Debt/Equity | 6.3 x |
Debt/Assets | 1.5 x |
Financial Leverage | 4.1 x |
Rubius Therapeutics has 1.04k Twitter Followers. The number of followers has increased 2.7% month over month and increased 5.6% quarter over quarter
290
Tweets
251
Following
1k
Followers
11
Tweets last 30 days
5.3
Avg. likes per Tweet
100%
Tweets with engagement
When was Rubius Therapeutics founded?
Rubius Therapeutics was founded in 2013.
Who are Rubius Therapeutics key executives?
Rubius Therapeutics's key executives are Pablo J. Cagnoni, Christina Coughlin and Andrew Oh.
How many employees does Rubius Therapeutics have?
Rubius Therapeutics has 174 employees.
Who are Rubius Therapeutics competitors?
Competitors of Rubius Therapeutics include ImCheck Therapeutics, Confo Therapeutics and Opthea.
Where is Rubius Therapeutics headquarters?
Rubius Therapeutics headquarters is located at 399 Binney St #300, Cambridge.
Where are Rubius Therapeutics offices?
Rubius Therapeutics has offices in Cambridge and Smithfield.
How many offices does Rubius Therapeutics have?
Rubius Therapeutics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies